Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk


5/27/2021 Top 20 Online Pharmaceutical Retailers in Russia (Q1 2021)

Between January and March 2021, the total volume of the online sales or reservation of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia amounted to 46.2 million rubles (end-user prices, VAT included), 24% up from the first quarter of 2020, which is, considering the drop in the total volume of the Russian pharmaceutical and parapharmaceutical market, is a real success. However, it should be noted that it was parapharmaceuticals that contributed the most. The growth rate of the online sales and reservation of pharmaceutical drugs was +13.4%, and while this is a lot, it is still 6.7% down from 2020. Besides, the laws prohibiting the online sale of Rx drugs is an objective obstacle.

5/26/2021 Ranking of Russian Pharmacy Chains (Q1 2021)

Another wave of consolidation processes was the highlight of May 2021 for the so-called “big” Russian retail. May saw three major transactions at once: Magnit is purchasing Dixy, Lenta is acquiring Billa, and finally a large association will be formed for by consolidating certain aspects of the activities of three regional retailers in Siberia and the Far East – Krasny Yar, Samberi and Slata.

5/25/2021 Database Update: Audit of Veterinary Drug Retail Sales in Russia (April 2021)

The veterinary market in Russia kept stagnating between January and April 2021. The growth rate is only +1.7% in monetary terms, with the sales volume of 6.93 billion rubles (retail prices, VAT included). In fact, the growth rate was positive mostly due to inflation, while the sales in physical terms kept decreasing. The sales volume in physical terms amounted to 53.9 million minimum dosage units (MDU), down 8.5% from January–April 2020.

5/20/2021 Ranking of Russian Pharmaceutical Distributors (Q1 2021)

A reduction in market volumes was the highlight of early 2021 for the pharmaceutical industry. However, only retail has been on the decline so far. All the segments in the public sector has been showing double-digit growth rates, which helped the growth rates of the market on the whole, but the positive growth rates are only nominal, due to the inflation rate in the first quarter of 2021 being thrice as high as the growth rate.

5/19/2021 Veterinary Vaccine Import to Russia in 2020

In 2020, Russia imported 15.32 billion rubles worth of veterinary vaccines (customs clearance included) from foreign countries except the EEU member states, down 9.4% in monetary terms (rubles) from 2019, because the importers were using up their stocks made in late 2019. The import volume in physical terms amounted to 7.15 million units, or around 43.4 billion dosages. The growth rates are -23.3% in units and -23.1% in dosages.

5/14/2021 Import of Veterinary Vaccines and Serums from EEU Countries to Russia in 2020

Russia imported 0.09 billion rubles worth of veterinary vaccines and serums from the EEU countries in 2020 (wholesale prices, VAT excluded). However, most of the products were not manufactured by the EEU member states. Manufacturers from Belarus and Kazakhstan together accounted for only 0.8% of the total import volume, and Armenia and Kyrgyzstan did not ship veterinary vaccines to Russia in 2020 at all.

4/30/2021 API Import to Russia in 2020

The total volume of API import to Russia reached an all-time high in 2020 in both monetary and physical terms, amounting to 14.4 thousand tons of APIs, worth 167.1 billion rubles (customs clearance and VAT included). The growth rates are +26.6% in monetary and +13% in physical terms.

4/29/2021 Pharmaceutical Drug Production in Russia (March 2021)

Russian manufacturers produced 149.6 billion rubles worth of pharmaceutical drugs between January and March 2021 (manufacturer’s prices, VAT included), up 47% from the same period last year in monetary terms (rubles). While it is early to make predictions, it has been the highest growth rate in five years. The growth rate in physical terms (units) was +7%, with the production volume of 1.07 billion units. The growth rate was even lower, if calculated in MDUs (minimum dosage units), reaching 4.2%, with the production volume of 19.4 billion MDUs.

4/28/2021 Import of Veterinary Drugs and Feed Supplements to Russia (December 2020)

Russia imported 34.5 billion rubles worth of veterinary drugs in 2020 (customs clearance and VAT included), down 8.4% in monetary terms (rubles) from 2019. The seemingly negative growth rate was due to the high-base effect, since back in 2019, the market players had stocked up their warehouses to get ready for the upcoming regulatory changes. As for feed supplements, the import volume amounted to 40.2 billion rubles, with the growth rate of +10.5%.

4/21/2021 RNC Pharma Study: Features of the Commodity Circulation in the Commercial Pharmaceutical Market in Russia in 2020

At the first stage of the movement, more than 82% of all goods are shipped from distributors to the final destination, which is pharmacies, healthcare facilities and others. Pharmacies are, without a doubt, the main channel for the commercial market, accounting for more than 75% of the total volume of the first stage shipments. Another 5% are shipped to the warehouses of pharmacy chains, and then the goods are redistributed to specific points of sale by the pharmacy chain’s own logistics services.